Even if it is delayed a bit, cant they manufacture and distribute hema in Europe and Asia? Way bigger market by at least 10 fold. I am sure that has crossed the mind of David Koos, PhD.
Jun 11, 2014 - Announce research paper on the use of gene-silencing in heart transplants, showing multiple applications of dCellVax technology; dCellVax IND planned for August 2014. http://ih.advfn.com/p.php?pid=nmona&article=62529632
** All dates listed above refer to the date of the linked PR **
We can see from this timeline that Regen has carefully put together a unique approach for treating cancer by immunotherapy, based on the combination of technology obtained from WP Min and Benitec BioPharma. It is curious that they anticipated an IND submission in Q4 of 2013 as recent as August of last year, but you can see that the timeline gets more realistic once they recruited Dr. David Suhy (who, by the way, "was essential in the development of the gene-based hepatitis drug in collaboration with Pfizer"). It's nice see the June 11th dCellVax update, as it had been several months since they released anything about this product. We are only 35 calendar days out from the start of August, so I'm confident we'll see this IND actually submitted.
Can you believe that the cherry-on-top of the anticipated Regen BioPharma IPO and FDA approval of HemaXellerate I is a cancer immunotherapeutic?! :-)